Next Generation Targets for Immuno-Oncology

Anthony received his Ph.D. in Cell Biology and Anatomy at the University of Arizona where his research concentrated on understanding the molecular mechanisms of cardiac valve development. He moved onto a Postdoctoral Research Fellowship at the University of Minnesota where he utilized zebrafish and mouse model systems to uncover new genes involved in kidney and heart development and also published the genetic cause of the dwarfing syndrome in humans called dominant Robinow Syndrome. Anthony spent time in the Stem Cell biotech industry using mRNA overexpression to reprogram somatic cells to pluripotency as well as transdifferentiating one cell type into another. Finally, Anthony has been at R&D Systems for the last 8 years working as a Manager and then Director in the Protein Development Department. Anthony has over 12 years of Biotech industry experience and is focused on offering the highest quality recombinant proteins to customers. New protein product offerings in the Immuno-oncology area is a major focus for R&D Systems as so many academic and biotech/pharma labs are entering this area with the success of both antibody immunotherapy as well as CAR T or CAR NK research and therapies.